Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. WST
WST logo

WST Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
328.440
Open
323.500
VWAP
323.49
Vol
1.03M
Mkt Cap
23.03B
Low
316.100
Amount
334.29M
EV/EBITDA(TTM)
26.10
Total Shares
70.65M
EV
22.71B
EV/OCF(TTM)
31.75
P/S(TTM)
7.34
West Pharmaceutical Services, Inc. is a global manufacturer that is engaged in the design and production of technologically advanced, integrated containment and delivery systems for injectable drugs and healthcare products. The Company operates in two segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers elastomers & primary containment, drug delivery devices, integrated solutions, and analytical lab services, primarily to biologic, generic, and pharmaceutical drug customers. The Contract-Manufactured Products reportable segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. This segment manufactures customer-owned components and devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products.
Show More

Events Timeline

(ET)
2026-04-23
10:00:00
United Rentals and Others See Notable Gains This Morning
select
2026-04-23
09:10:00
Markets Pull Back as Oil Prices Return Above $100
select
2026-04-23
06:20:00
Company Sees Q2 Revenue of $830M-$850M
select
2026-04-23
06:20:00
Raises FY26 Revenue Outlook to $3.3B-$3.35B
select
2026-04-23
06:10:00
Company Reports Q1 Revenue of $844.9M Exceeding Expectations
select

News

Newsfilter
1.0
04-28Newsfilter
West Pharmaceutical Services to Present at Upcoming Investor Conferences
  • Investor Conference Schedule: West Pharmaceutical Services will participate in the Bank of America Global Healthcare Conference on May 12, 2026, and the William Blair Annual Growth Stock Conference on June 2, 2026, showcasing its innovative solutions in injectable drug administration, which is expected to attract investor interest and enhance the company's visibility.
  • Webcast Availability: The live webcasts for these events will be accessible in the Investors section of the company's website, with replays available for approximately 90 days post-event, enhancing transparency and fostering interaction with potential investors.
  • Company Performance Overview: West reported net sales of $3.07 billion in fiscal year 2025, demonstrating strong performance in the global injectable solutions market, further solidifying its position as an industry leader.
  • Global Business Footprint: With over 10,000 employees across 50 sites, including 26 manufacturing facilities, West delivers over 41 billion components and devices annually, enabling effective support for drug developers and enhancing its competitive edge in the market.
NASDAQ.COM
8.0
04-27NASDAQ.COM
Analysis of WST Dividend Expectations and Stock Performance
  • Dividend Yield Analysis: WST's estimated annualized dividend yield stands at 0.29%, and while dividends are not always predictable, historical data aids in assessing the likelihood of future dividends, thereby influencing investor return expectations.
  • Stock Price Range: WST's 52-week low is $202.79 per share, with a high of $322.34, and the latest trade at $308.61 indicates that the stock is fluctuating near its high, which may affect investors' buying decisions.
  • ETF Holding Proportion: According to ETF Channel, WST constitutes 4.44% of the Virtus KAR Mid-Cap ETF (KMID), which is trading down about 0.4% on the day, potentially reflecting overall market sentiment towards mid-cap stocks.
  • Intraday Stock Performance: In Monday trading, shares of West Pharmaceutical Services, Inc. are up about 0.7%, indicating a positive short-term market reaction to the company, which may attract more investor attention.
moomoo
6.0
04-27moomoo
BARCLAYS INCREASES TARGET PRICE FOR WEST PHARMACEUTICAL SERVICES INC TO $310, UP FROM $275
  • Company Overview: West Pharmaceutical Services is a key player in the pharmaceutical industry, providing essential services and products.

  • Target Price Increase: Barclays has raised the target price for West Pharmaceutical Services from $275 to $310, indicating a positive outlook for the company's stock.

CNBC
2.0
04-25CNBC
Semiconductor Stocks Overbought Amid Market Rally
  • Semiconductor Surge: Semiconductor stocks emerged as a focal point for investors this week, with the S&P 500 and Nasdaq rising 0.55% and 1.50% respectively, pushing the market to new highs and reflecting strong optimism in the sector.
  • Overbought Indicators: CNBC Pro's analysis identified stocks with a 14-day RSI above 70 as overbought, indicating potential pullback risks, particularly as the iShares Semiconductor ETF (SOXX) posted an 11.04% gain this week, showcasing robust enthusiasm for chipmakers.
  • Earnings Drive: Texas Instruments reported first-quarter earnings that exceeded expectations, highlighting strong demand for its analog chips, which significantly boosted its stock price and reinforced market confidence in the semiconductor industry.
  • Narrowing Market Leadership: Cameron Dawson, Chief Investment Officer at NewEdge Wealth, noted that market leadership is increasingly concentrated in the semiconductor sector, indicating a sustained rise in investor focus on this industry, which may impact the performance of other sectors.
NASDAQ.COM
4.5
04-23NASDAQ.COM
US Stocks Close Lower Amid Iran Tensions and Mixed Economic Data
  • Market Weakness: On Thursday, the S&P 500 index fell by 0.41%, the Dow Jones Industrial Average dropped by 0.36%, and the Nasdaq 100 declined by 0.57%, reflecting heightened investor concerns over the escalating tensions in Iran, which erased earlier gains.
  • Mixed Economic Data: Weekly initial unemployment claims rose by 6,000 to 214,000, indicating a weaker labor market than the expected 210,000, while the Chicago Fed national activity index fell to -0.20, signaling a slowdown in economic growth.
  • Rising Oil Prices: WTI crude oil prices surged over 3% due to tensions in the Strait of Hormuz, potentially exacerbating the global energy crisis and influencing market sentiment and inflation expectations.
  • Earnings Reports Highlight: Despite the overall market weakness, 81% of S&P 500 companies reported better-than-expected earnings, with Q1 earnings projected to rise by 12% year-over-year, showcasing resilience in certain sectors, particularly chipmakers like Texas Instruments, which rose over 19%.
NASDAQ.COM
4.5
04-23NASDAQ.COM
US Stocks Slightly Up, Led by Chipmakers
  • Chipmaker Rally: Texas Instruments (TXN) surged over 16% after reporting Q1 revenue of $4.83 billion, exceeding the consensus of $4.53 billion, and forecasting Q2 revenue between $5.00 billion and $5.40 billion, solidifying its leadership in the semiconductor market.
  • Strong Rental Performance: United Rentals (URI) saw its stock rise over 20% after posting Q1 revenue of $3.99 billion, above the consensus of $3.88 billion, and raising its full-year revenue forecast to $16.9 billion-$17.4 billion, indicating robust market demand and growth potential.
  • Software Sector Weakness: ServiceNow (NOW) dropped more than 16% after cutting its full-year gross margin forecast to 81.5%, below the consensus of 82.1%, reflecting challenges in the software industry that may impact investor confidence.
  • Mixed Economic Data: Weekly initial jobless claims rose to 214,000, exceeding expectations of 210,000, indicating a weaker labor market, while the April S&P manufacturing PMI increased to 54.0, surpassing expectations of 52.5, suggesting a rebound in manufacturing activity.
Wall Street analysts forecast WST stock price to rise
12 Analyst Rating
Wall Street analysts forecast WST stock price to rise
10 Buy
2 Hold
0 Sell
Strong Buy
Current: 0.000
sliders
Low
285.00
Averages
348.70
High
375.00
Current: 0.000
sliders
Low
285.00
Averages
348.70
High
375.00
Morgan Stanley
Equal Weight
maintain
$285 -> $315
AI Analysis
2026-04-27
Reason
Morgan Stanley
Price Target
$285 -> $315
AI Analysis
2026-04-27
maintain
Equal Weight
Reason
Morgan Stanley raised the firm's price target on West Pharmaceutical to $315 from $285 and keeps an Equal Weight rating on the shares.
Barclays
Equal Weight
maintain
$275 -> $310
2026-04-27
Reason
Barclays
Price Target
$275 -> $310
2026-04-27
maintain
Equal Weight
Reason
Barclays raised the firm's price target on West Pharmaceutical to $310 from $275 and keeps an Equal Weight rating on the shares. The firm updated the company's model following the Q1 upside.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for WST
Unlock Now

Valuation Metrics

The current forward P/E ratio for West Pharmaceutical Services Inc (WST.N) is 36.36, compared to its 5-year average forward P/E of 42.23. For a more detailed relative valuation and DCF analysis to assess West Pharmaceutical Services Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
42.23
Current PE
36.36
Overvalued PE
49.43
Undervalued PE
35.04

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
27.55
Current EV/EBITDA
23.90
Overvalued EV/EBITDA
32.75
Undervalued EV/EBITDA
22.35

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
7.81
Current PS
6.43
Overvalued PS
9.55
Undervalued PS
6.06

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

which stocks to buy short term
Intellectia · 40 candidates
Moving Average Relationship: PriceAboveMA20Week Price Change Pct: $4.00 - $12.00Is Index Component: GSPC
Ticker
Name
Market Cap$
top bottom
ELV logo
ELV
Elevance Health Inc
74.87B
QCOM logo
QCOM
Qualcomm Inc
158.82B
VTR logo
VTR
Ventas Inc
39.76B
KDP logo
KDP
Keurig Dr Pepper Inc
39.76B
PKG logo
PKG
Packaging Corp of America
18.95B
BKR logo
BKR
Baker Hughes Co
68.37B
daily top stock picks
Intellectia · 121 candidates
Market Cap: >= 2.00BRegion: USRsi Category: moderate, overboughtPrice Change Pct: >= $3.00List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20Monthly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
URI logo
URI
United Rentals Inc
50.48B
TXN logo
TXN
Texas Instruments Inc
215.15B
HRI logo
HRI
Herc Holdings Inc
3.60B
MOH logo
MOH
Molina Healthcare Inc
7.97B
STM logo
STM
STMicroelectronics NV
39.87B
WST logo
WST
West Pharmaceutical Services Inc
19.78B
what are the best stocks to buy today
Intellectia · 16 candidates
Market Cap: >= 10.00BRegion: USAnalyst Consensus: Strong Buy, Moderate BuyList Exchange: XNYS, XNAS, XASETarget Price Upside Potential: MoreAbovePriceMoving Average Relationship: PriceAboveMA20
Ticker
Name
Market Cap$
top bottom
NVDA logo
NVDA
NVIDIA Corp
4.65T
PDD logo
PDD
PDD Holdings Inc
150.14B
QCOM logo
QCOM
Qualcomm Inc
149.82B
SMFG logo
SMFG
Sumitomo Mitsui Financial Group, Inc
148.10B
SNY logo
SNY
Sanofi SA
114.04B
CEG logo
CEG
Constellation Energy Corp
106.46B
what is the best stock to invest 6/fev
Intellectia · 31 candidates
Market Cap: >= 10.00BAnalyst Consensus: Strong Buy, Moderate BuyEps 5yr Cagr: >= 10List Exchange: XNYS, XNAS, XASETarget Price Upside Potential: MoreAbovePriceIs Index Component: GSPC, NDX
Ticker
Name
Market Cap$
top bottom
BR logo
BR
Broadridge Financial Solutions Inc
22.70B
AMZN logo
AMZN
Amazon.com Inc
2.39T
NFLX logo
NFLX
Netflix Inc
340.62B
CRM logo
CRM
Salesforce Inc
177.98B
CCI logo
CCI
Crown Castle Inc
37.61B
DELL logo
DELL
Dell Technologies Inc
76.13B
show me stocks strong buy
Intellectia · 16 candidates
Analyst Consensus: Strong BuyEps 5yr Cagr: >= 5List Exchange: XNYS, XNAS, XASETarget Price Upside Potential: MoreAbovePriceIs Index Component: GSPCMonthly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
NVDA logo
NVDA
NVIDIA Corp
4.64T
MSFT logo
MSFT
Microsoft Corp
3.20T
AVGO logo
AVGO
Broadcom Inc
1.57T
ABT logo
ABT
Abbott Laboratories
190.06B
INTU logo
INTU
Intuit Inc
138.84B
BSX logo
BSX
Boston Scientific Corp
138.71B
tell me which stocks are now strong buy
Intellectia · 22 candidates
Market Cap Category: large, megaAnalyst Consensus: Strong BuyTarget Price Upside Potential: MoreAbovePriceIs Index Component: GSPCMonthly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
NVDA logo
NVDA
NVIDIA Corp
4.56T
MSFT logo
MSFT
Microsoft Corp
3.46T
AVGO logo
AVGO
Broadcom Inc
1.52T
MA logo
MA
Mastercard Inc
471.21B
ABT logo
ABT
Abbott Laboratories
186.79B
UBER logo
UBER
Uber Technologies Inc
171.03B
best stocks to invest in 2026 q1
Intellectia · 21 candidates
Market Cap: >= 5.00BMarket Cap Category: large, midAnalyst Consensus: Strong Buy, Moderate BuyReturn On Equity: >= 12.0%Target Price Upside Potential: MoreAbovePriceOne Month Predict Return: >= 5.0%
Ticker
Name
Market Cap$
top bottom
MORN logo
MORN
Morningstar Inc
8.63B
KSPI logo
KSPI
Kaspi.kz AO
14.51B
MANH logo
MANH
Manhattan Associates Inc
10.01B
LOGI logo
LOGI
Logitech International SA
13.49B
TTD logo
TTD
Trade Desk Inc
17.09B
PDD logo
PDD
PDD Holdings Inc
150.37B

Whales Holding WST

M
Moore Capital Management, LP
Holding
WST
+21.55%
3M Return
J
Jacobs Levy Equity Management Inc
Holding
WST
+9.98%
3M Return
N
Nan Shan Life Insurance Co., Ltd.
Holding
WST
+8.91%
3M Return
S
Stichting Pensioenfonds ABP
Holding
WST
+7.44%
3M Return
L
LGT Capital Partners Ltd.
Holding
WST
+6.31%
3M Return
A
AMI Asset Management Corp
Holding
WST
+5.80%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is West Pharmaceutical Services Inc (WST) stock price today?

The current price of WST is 325.92 USD — it has increased 1.21

What is West Pharmaceutical Services Inc (WST)'s business?

West Pharmaceutical Services, Inc. is a global manufacturer that is engaged in the design and production of technologically advanced, integrated containment and delivery systems for injectable drugs and healthcare products. The Company operates in two segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers elastomers & primary containment, drug delivery devices, integrated solutions, and analytical lab services, primarily to biologic, generic, and pharmaceutical drug customers. The Contract-Manufactured Products reportable segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. This segment manufactures customer-owned components and devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products.

What is the price predicton of WST Stock?

Wall Street analysts forecast WST stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for WST is348.70 USD with a low forecast of 285.00 USD and a high forecast of 375.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is West Pharmaceutical Services Inc (WST)'s revenue for the last quarter?

West Pharmaceutical Services Inc revenue for the last quarter amounts to 844.90M USD, increased 21.05

What is West Pharmaceutical Services Inc (WST)'s earnings per share (EPS) for the last quarter?

West Pharmaceutical Services Inc. EPS for the last quarter amounts to 1.92 USD, increased 56.10

How many employees does West Pharmaceutical Services Inc (WST). have?

West Pharmaceutical Services Inc (WST) has 10800 emplpoyees as of May 10 2026.

What is West Pharmaceutical Services Inc (WST) market cap?

Today WST has the market capitalization of 23.03B USD.